ESTREPTOQUINASE MICROBIANA: AVANÇOS E PERSPECTIVAS NO TRATAMENTO DE DOENÇAS CARDIOVASCULARES
ESTREPTOQUINASE MICROBIANA: AVANÇOS E PERSPECTIVAS NO TRATAMENTO DE DOENÇAS CARDIOVASCULARES
-
DOI: https://doi.org/10.22533/at.ed.76224140513
-
Palavras-chave: estreptoquinase, agente fibrinolítico, tromboembolismo, infarto.
-
Keywords: streptokinase, fibrinolytic, thromboembolism, heart attack.
-
Abstract: Cardiovascular diseases are currently one of the leading causes of death and hospitalizations in Brazil, making it necessary to study new medications for treatment. Streptokinase, an enzyme produced by Streptococcus spp., belongs to the class of medications known as fibrinolytics, used in the treatment of acute myocardial infarction and thromboembolism. This enzyme degrades the fibrin matrix of a thrombus, causing its dissolution. The timing is critical for treatment success and a several individuals died before receiving medical attention. Therefore, this work aims to conduct a bibliographical review of the use of streptokinase in the treatment of acute arterial occlusion in patients post-acute myocardial infarction and post- catheterization.
- Cristiani Baldo da Rocha
- Beatriz Peres Sanches
- Camila Cristina Valentim
- Giulia Mian Assi
- Janaina Mantovan
- Giovana Elika Silveira Bertoncini